Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

References

• John WS, Provan D, Bernadette Garvey M, Freedman J. Recent progress in understanding the pathogenesis of immune Thrombocytopenia. Curr Opin Hematol. 2010;17(6):590–595. doi:10.1097/MOH.0b013e32833eaef320739879
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–6521. doi:10.1182/blood-2009-01-12915519395674
   PubMed Web of Science ®Google Scholar
• Schulze H, Gaedicke G. Immune thrombocytopenia in children and adults: what’s the same, what’s different? Haematologica. 2011;96(12):1739–1741. doi:10.3324/haematol.2011.05583022147771
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008.11919310
   PubMed Web of Science ®Google Scholar
• Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am. 2009;23(6):1213–1221.19932429
   PubMed Web of Science ®Google Scholar
• Palandri F, Catani L, Auteri G, et al. Understanding how older age drives decision-making and outcome in immune thrombocytopenia. a single centre study on 465 adult patients. Br J Haematol. 2019;184(3):424–430.30408157
   PubMed Web of Science ®Google Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–125.12848952
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of Incident Immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315.25305203
   PubMed Web of Science ®Google Scholar
• Mahévas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. Br J Haematol. 2016;173(6):844–856.27062054
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.31770441
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.201900096631794604
   PubMed Web of Science ®Google Scholar
• Lambert MP, Gernsheimer TB. Clinical updates in adult immune Thrombocytopenia. Blood. 2017;129(21):2829–2835. doi:10.1182/blood-2017-03-75411928416506
   PubMed Web of Science ®Google Scholar
• Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172(2):262–273. doi:10.1111/bjh.1382726537623
   PubMed Web of Science ®Google Scholar
• González-López TJ, Sánchez-González B, Jarque I, et al. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. Eur J Haematol. 2019.
   Web of Science ®Google Scholar
• Depré F, Aboud N, Mayer B, Salama A. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice. PLoS One. 2018;13(6):e0198184. doi:10.1371/journal.pone.019818429856800
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-16250319005182
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi:10.1182/blood-2009-06-22556519846889
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-67459811
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International working group. Blood. 2013;121(14):2596–2606. doi:10.1182/blood-2012-07-44239223361904
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016;91(9):907–911. doi:10.1002/ajh.2443427220625
   PubMed Web of Science ®Google Scholar
• Saleh MN, Fisher M, Grotzinger KM. Analysis of the impact and burden of illness of adult chronic ITP in the US. Curr Med Res Opin. 2009;25(12):2961–2969. doi:10.1185/0300799090336238819835465
   PubMed Web of Science ®Google Scholar
• Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009;84(10):631–635. doi:10.1002/ajh.2150019705429
   PubMed Web of Science ®Google Scholar
• Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455–468. doi:10.1016/0021-9681(70)90054-826309916
   PubMedGoogle Scholar
• Onder G, Vetrano DL, Marengoni A, Bell JS, Johnell K, Palmer K. Optimising Pharmacotherapy through Pharmacoepidemiology Network (OPPEN). Accounting for frailty when treating chronic diseases. Eur J Intern Med. 2018;56:49–52. doi:10.1016/j.ejim.2018.02.02129526651
   PubMed Web of Science ®Google Scholar
• Zucchelli A, Vetrano DL, Marengoni A, et al. Frailty predicts short-term survival even in older adults without multimorbidity. Eur J Intern Med. 2018;56:53–56. doi:10.1016/j.ejim.2018.06.01229950278
   PubMed Web of Science ®Google Scholar
• Boulware R, Refaai MA. Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia? Thromb Res. 2020;187(187):154–158. doi:10.1016/j.thromres.2020.01.02032004875
   PubMed Web of Science ®Google Scholar
• Watad A, Bragazzi NL, Adawi M, et al. Autoimmunity in the elderly: insights from basic science and clinics - a mini-review. Gerontology. 2017;63(6):515–523. doi:10.1159/00047801228768257
   PubMed Web of Science ®Google Scholar
• González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E403. doi:10.1002/ajh.23900
   Web of Science ®Google Scholar
• Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017;1(24):2295–2301.29296878
   PubMed Web of Science ®Google Scholar
• Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755–2762.20130241
   PubMed Web of Science ®Google Scholar
• Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11):1976–1981.23293082
   PubMed Web of Science ®Google Scholar
• Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500–503.25972158
   PubMed Web of Science ®Google Scholar
• Lucchini E, Fanin R, Cooper N, Zaja F. Management of immune thrombocytopenia in elderly patients. Eur J Intern Med. 2018;58:70–76.30274902
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123(25):3906–3908.24802773
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang M, Du X, Cheng Y, Cheng G. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia. Br J Haematol. 2020.
   Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128(12):1625–1630.27354722
   PubMed Web of Science ®Google Scholar